The emerging role of PET imaging in dementia.

[en] A compelling need in the field of neurodegenerative diseases is the development and validation of biomarkers for early identification and differential diagnosis. The availability of positron emission tomography (PET) neuroimaging tools for the assessment of molecular biology and neuropathology has opened new venues in the diagnostic design and the conduction of new clinical trials. PET techniques, allowing the in vivo assessment of brain function and pathology changes, are increasingly showing great potential in supporting clinical diagnosis also in the early and even preclinical phases of dementia. This review will summarize the most recent evidence on fluorine-18 fluorodeoxyglucose-, amyloid -, tau -, and neuroinflammation - PET tools, highlighting strengths and limitations and possible new perspectives in research and clinical applications. Appropriate use of PET tools is crucial for a prompt diagnosis and target evaluation of new developed drugs aimed at slowing or preventing dementia.

Disciplines :

Radiology, nuclear medicine & imaging

Author, co-author :

Iaccarino, Leonardo

Sala, Arianna ; UniSR

Caminiti, Silvia Paola

Perani, Daniela

Language :

English

Title :

The emerging role of PET imaging in dementia.

Publication date :

2017

Journal title :

F1000Research

eISSN :

2046-1402

Publisher :

F1000 Research Ltd, London, United Kingdom

Volume :

Pages :

1830

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 02 June 2021

Statistics

Number of views

54 (5 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Albert MS DeKosky ST Dickson D: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-9. 21514249 10.1016/j.jalz.2011.03.008 3312027
Gorno-Tempini ML Hillis AE Weintraub S: Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-14. 21325651 10.1212/WNL.0b013e31821103e6 3059138 F1000 Recommendation
McKhann GM Knopman DS Chertkow H: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9. 21514250 10.1016/j.jalz.2011.03.005 3312024
Rascovsky K Hodges JR Knopman D: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-77. 21810890 10.1093/brain/awr179 3170532 F1000 Recommendation
Sperling RA Aisen PS Beckett LA: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-92. 21514248 10.1016/j.jalz.2011.03.003 3220946
Armstrong MJ Litvan I Lang AE: Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. 23359374 10.1212/WNL.0b013e31827f0fd1 3590050
Dubois B Feldman HH Jacova C: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-29. 24849862 10.1016/S1474-4422(14)70090-0 F1000 Recommendation
McKeith IG Dickson DW Lowe J: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-72. 16237129 10.1212/01.wnl.0000187889.17253.b1
Perani D: FDG-PET and amyloid-PET imaging: the diverging paths. Curr Opin Neurol. 2014;27(4):405-13. 24927239 10.1097/WCO.0000000000000109
Caroli A Prestia A Chen K: Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012;53(4):592-600. 22343502 10.2967/jnumed.111.094946 3640308
Frisoni GB Bocchetta M Chételat G: Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81(5):487-500. 23897875 10.1212/WNL.0b013e31829d86e8 3776529 F1000 Recommendation
Perani D Schillaci O Padovani A: A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int. 2014;2014: 785039. 24772437 10.1155/2014/785039 3977528
Frisoni GB Perani D Bastianello S: Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. Neurobiol Aging. 2017;52:119-31. 28317643 10.1016/j.neurobiolaging.2016.02.033
Sokoloff L: Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab. 1981;1(1):7-36. 7035471 10.1038/jcbfm.1981.4
Kadekaro M Vance WH Terrell ML: Effects of antidromic stimulation of the ventral root on glucose utilization in the ventral horn of the spinal cord in the rat. Proc Natl Acad Sci U S A. 1987;84(15):5492-5. 3474665 10.1073/pnas.84.15.5492 298885
Pellerin L Magistretti PJ: Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A. 1994;91(22):10625-9. 7938003 10.1073/pnas.91.22.10625 45074
Lundgaard I Li B Xie L: Direct neuronal glucose uptake heralds activity-dependent increases in cerebral metabolism. Nat Commun. 2015;6: 6807. 25904018 10.1038/ncomms7807 4410436 F1000 Recommendation
Zimmer ER Parent MJ Souza DG: [ 18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20(3):393-5. 28135241 10.1038/nn.4492 5378483
Kato T Inui Y Nakamura A: Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev. 2016;30:73-84. 26876244 10.1016/j.arr.2016.02.003
Teune LK Bartels AL de Jong BM: Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25(14):2395-404. 20669302 10.1002/mds.23291
Iaccarino L Crespi C Della Rosa PA: The semantic variant of primary progressive aphasia: clinical and neuroimaging evidence in single subjects. PLoS One. 2015;10(3):e0120197. 25756991 10.1371/journal.pone.0120197 4354903
Teipel S Drzezga A Grothe MJ: Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurol. 2015;14(10):1037-53. 26318837 10.1016/S1474-4422(15)00093-9
Cerami C Dodich A Greco L: The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia. J Alzheimers Dis. 2017;55(1):183-97. 27662315 10.3233/JAD-160682 5115609
Cerami C Dodich A Lettieri G: Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia. Cortex. 2016;83:101-12. 27498041 10.1016/j.cortex.2016.07.008
Perani D Cerami C Caminiti SP: Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging. 2016;43(3):499-508. 26341365 10.1007/s00259-015-3170-y
Caminiti SP Alongi P Majno L: Evaluation of an optimized [ 18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. Eur J Neurol. 2017;24(5):687-e26. 28244178 10.1111/ene.13269
Bateman RJ Xiong C Benzinger TL: Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. 22784036 10.1056/NEJMoa1202753 3474597 F1000 Recommendation
Chételat G Desgranges B Landeau B: Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain. 2008;131(Pt 1):60-71. 18063588 10.1093/brain/awm288
Cerami C Crespi C Della Rosa PA: Brain changes within the visuo-spatial attentional network in posterior cortical atrophy. J Alzheimers Dis. 2015;43(2):385-95. 25114070 10.3233/JAD-141275
Perani D Della Rosa PA Cerami C: Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 2014;6:445-54. 25389519 10.1016/j.nicl.2014.10.009 4225527
Berti V Polito C Lombardi G: Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurol Sci. 2016;37(5):663-72. 26792010 10.1007/s10072-016-2477-1
Cerami C Della Rosa PA Magnani G: Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. Neuroimage Clin. 2015;7:187-94. 25610780 10.1016/j.nicl.2014.12.004 4300010
Iaccarino L Chiotis K Alongi P: A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. J Alzheimers Dis. 2017;59(2):603-14. 28671117 10.3233/JAD-170158
Garibotto V Herholz K Boccardi M: Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:183-95. 28317648 10.1016/j.neurobiolaging.2016.03.033 F1000 Recommendation
Perani D: FDG PET and cognitive symptoms of dementia. Clin Transl Imaging. 2013;1(4):247-60. 10.1007/s40336-013-0029-8
Potkin SG Anand R Fleming K: Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol. 2001;4(3):223-30. 11602028 10.1017/S1461145701002528
Smith GS Kramer E Ma Y: Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009;132(Pt 2):392-401. 19153152 10.1093/brain/awn326 2640217
Satoh M Ishikawa H Meguro K: Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol. 2010;64(6):337-44. 21071950 10.1159/000322121
Sultzer DL Melrose RJ Harwood DG: Effect of memantine treatment on regional cortical metabolism in Alzheimer's disease. Am J Geriatr Psychiatry. 2010;18(7):606-14. 20220580 10.1097/JGP.0b013e3181ca3a4e
Keller C Kadir A Forsberg A: Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. J Alzheimers Dis. 2011;24(1):109-23. 21157026 10.3233/JAD-2010-101290
Chow TW Fam D Graff-Guerrero A: Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study. Int J Geriatr Psychiatry. 2013;28(3):319-25. 22674572 10.1002/gps.3832 3467357
Smailagic N Vacante M Hyde C: 18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;1:CD010632. 25629415 10.1002/14651858.CD010632.pub2
Morbelli S Garibotto V Van De Giessen E: A Cochrane review on brain [ 18F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging. 2015;42(10):1487-91. 26067090 10.1007/s00259-015-3098-2
Friston KJ Holmes AP Worsley KJ: Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp. 1994;2(4):189-210. 10.1002/hbm.460020402
Minoshima S Koeppe RA Frey KA: Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994;35(9):1528-37. 8071705
Minoshima S Frey KA Koeppe RA: A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238-48. 7790950
Ishii K Willoch F Minoshima S: Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med. 2001;42(4):548-57. 11337540
Della Rosa PA Cerami C Gallivanone F: A standardized [ 18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12(4):575-93. 24952892 10.1007/s12021-014-9235-4
Lee DS Kang H Kim H: Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur J Nucl Med Mol Imaging. 2008;35(9):1681-91. 18491089 10.1007/s00259-008-0808-z
Huang S Li J Sun L: Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. Neuroimage. 2010;50(3):935-49. 20079441 10.1016/j.neuroimage.2009.12.120 3068623
Horwitz B Duara R Rapoport SI: Intercorrelations of glucose metabolic rates between brain regions: application to healthy males in a state of reduced sensory input. J Cereb Blood Flow Metab. 1984;4(4):484-99. 6501442 10.1038/jcbfm.1984.73
Pievani M Filippini N van den Heuvel MP: Brain connectivity in neurodegenerative diseases--from phenotype to proteinopathy. Nat Rev Neurol. 2014;10(11):620-33. 25287597 10.1038/nrneurol.2014.178
Morbelli S Drzezga A Perneczky R: Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging. 2012;33(11):2533-50. 22365486 10.1016/j.neurobiolaging.2012.01.005
Sanabria-Diaz G Martínez-Montes E Melie-Garcia L: Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One. 2013;8(7):e68860. 23894356 10.1371/journal.pone.0068860 3720883
Caminiti SP Tettamanti M Sala A: Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. J Cereb Blood Flow Metab. 2017;37(4):1311-25. 27306756 10.1177/0271678X16654497 5453453
Sala A Caminiti SP Presotto L: Altered brain metabolic connectivity at multiscale level in early Parkinson's disease. Sci Rep. 2017;7(1): 4256. 28652595 10.1038/s41598-017-04102-z 5484707
Agdeppa ED Kepe V Liu J: Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001;21(24):RC189. 11734604
Masdeu JC: Future Directions in Imaging Neurodegeneration. Curr Neurol Neurosci Rep. 2017;17(1):9. 28210978 10.1007/s11910-017-0718-1
Landau SM Thomas BA Thurfjell L: Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41(7):1398-407. 24647577 10.1007/s00259-014-2753-3 4055504
Minoshima S Drzezga AE Barthel H: SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. J Nucl Med. 2016;57(8):1316-22. 27481605 10.2967/jnumed.116.174615
Klunk WE Koeppe RA Price JC: The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1-15.e1-4. 25443857 10.1016/j.jalz.2014.07.003 4300247
Klunk WE Engler H Nordberg A: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-19. 14991808 10.1002/ana.20009
Choi SR Schneider JA Bennett DA: Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26(1):8-16. 22354138 10.1097/WAD.0b013e31821300bc 3286131
Wolk DA Grachev ID Buckley C: Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68(11):1398-403. 21747004 10.1001/archneurol.2011.153 4532383
Sabri O Sabbagh MN Seibyl J: Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11(8):964-74. 25824567 10.1016/j.jalz.2015.02.004
Seo SW Ayakta N Grinberg LT: Regional correlations between [ 11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2017;13:130-7. 27981028 10.1016/j.nicl.2016.11.008 5144753
Herrup K: The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18(6):794-9. 26007212 10.1038/nn.4017 F1000 Recommendation
Villemagne VL Doré V Bourgeat P: Aβ-amyloid and Tau Imaging in Dementia. Semin Nucl Med. 2017;47(1):75-88. 27987560 10.1053/j.semnuclmed.2016.09.006
Chételat G Ossenkoppele R Villemagne VL: Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain. 2016;139(Pt 9):2528-39. 27357349 10.1093/brain/aww159
Johnson KA Minoshima S Bohnen NI: Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 2013;9(4):e106-9. 23809369 10.1016/j.jalz.2013.06.001
Guerra UP Nobili FM Padovani A: Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci. 2015;36(6):1075-81. 25616445 10.1007/s10072-015-2079-3
Nordberg A Carter SF Rinne J: A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40(1):104-14. 22961445 10.1007/s00259-012-2237-2 3510420
Hatashita S Wakebe D: Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging. J Alzheimers Dis. 2017;57(3):765-73. 28304292 10.3233/JAD-161074
Jack CR Jr Wiste HJ Lesnick TG: Brain β-amyloid load approaches a plateau. Neurology. 2013;80(10):890-6. 23446680 10.1212/WNL.0b013e3182840bbe 3653215
Villemagne VL Pike KE Chételat G: Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181-92. 21280088 10.1002/ana.22248 3045039
Petersen RC Aisen P Boeve BF: Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74(2):199-208. 23686697 10.1002/ana.23931 3804562 F1000 Recommendation
Landau SM Horng A Fero A: Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86(15):1377-85. 26968515 10.1212/WNL.0000000000002576 4831042
Chételat G La Joie R Villain N: Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013;2:356-65. 24179789 10.1016/j.nicl.2013.02.006 3777672
Rabinovici GD Rosen HJ Alkalay A: Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):2034-42. 22131541 10.1212/WNL.0b013e31823b9c5e 3236517
Jansen WJ Ossenkoppele R Knol DL: Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-38. 25988462 10.1001/jama.2015.4668 4486209 F1000 Recommendation
Ossenkoppele R Jansen WJ Rabinovici GD: Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939-49. 25988463 10.1001/jama.2015.4669 4517678 F1000 Recommendation
Lehmann M Ghosh PM Madison C: Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain. 2013;136(Pt 3):844-58. 23358601 10.1093/brain/aws327 3580269 F1000 Recommendation
Dronse J Fliessbach K Bischof GN: In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. J Alzheimers Dis. 2017;55(2):465-71. 27802224 10.3233/JAD-160316
Maetzler W Liepelt I Reimold M: Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34(1):107-12. 19162186 10.1016/j.nbd.2008.12.008
Kantarci K Lowe VJ Boeve BF: AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017;81(1):58-67. 27863444 10.1002/ana.24825 5299616
Baron JC Farid K Dolan E: Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab. 2014;34(5):753-8. 24619277 10.1038/jcbfm.2014.43 4013776
Gurol ME Dierksen G Betensky R: Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology. 2012;79(4):320-6. 22786597 10.1212/WNL.0b013e31826043a9 3400097 F1000 Recommendation
Nordberg A: Dementia in 2014. Towards early diagnosis in Alzheimer disease. Nat Rev Neurol. 2015;11(2):69-70. 25623789 10.1038/nrneurol.2014.257
Roberts BR Lind M Wagen AZ: Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: correlation with amyloid PET. Brain. 2017;140(5):1486-1498. 28383676 10.1093/brain/awx057
Villemagne VL Burnham S Bourgeat P: Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-67. 23477989 10.1016/S1474-4422(13)70044-9 F1000 Recommendation
van Berckel BN Ossenkoppele R Tolboom N: Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570-6. 23940304 10.2967/jnumed.112.113654
Edison P Hinz R Ramlackhansingh A: Can target-to-pons ratio be used as a reliable method for the analysis of [ 11C]PIB brain scans? Neuroimage. 2012;60(3):1716-23. 22306804 10.1016/j.neuroimage.2012.01.099
Schwarz CG Senjem ML Gunter JL: Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. Neuroimage. 2017;144(Pt A):113-27. 27577718 10.1016/j.neuroimage.2016.08.056 5183471
Heurling K Leuzy A Jonasson M: Quantitative positron emission tomography in brain research. Brain Res. 2017;1670:220-34. 28652218 10.1016/j.brainres.2017.06.022
Lammertsma AA: Forward to the Past: The Case for Quantitative PET Imaging. J Nucl Med. 2017;58(7):1019-24. 28522743 10.2967/jnumed.116.188029
Doody RS Thomas RG Farlow M: Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311-21. 24450890 10.1056/NEJMoa1312889 F1000 Recommendation
Salloway S Sperling R Fox NC: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322-33. 24450891 10.1056/NEJMoa1304839 4159618 F1000 Recommendation
Sevigny J Chiao P Bussière T: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50-6. 27582220 10.1038/nature19323 F1000 Recommendation
Kayed R Lasagna-Reeves CA: Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis. 2013;33Suppl 1:S67-78. 22531422 10.3233/JAD-2012-129001
Haass C Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-12. 17245412 10.1038/nrm2101
Hedden T Oh H Younger AP: Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013;80(14):1341-8. 23547267 10.1212/WNL.0b013e31828ab35d 3656457 F1000 Recommendation
Jack CR Jr Wiste HJ Weigand SD: Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732-40. 24132377 10.1212/01.wnl.0000435556.21319.e4 3821718
Ossenkoppele R van der Flier WM Verfaillie SC: Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology. 2014;82(20):1768-75. 24748672 10.1212/WNL.0000000000000432
Jagust WJ Landau SM Alzheimer's Disease Neuroimaging Initiative: Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci. 2012;32(50):18227-33. 23238736 10.1523/JNEUROSCI.3266-12.2012 3537830
Okamura N Harada R Furumoto S: Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14(11):500. 25239654 10.1007/s11910-014-0500-6
Villemagne VL Okamura N: In vivo tau imaging: obstacles and progress. Alzheimers Dement. 2014;10(3 Suppl):S254-64. 24924676 10.1016/j.jalz.2014.04.013
Villemagne VL Okamura N: Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Curr Opin Neurobiol. 2016;36:43-51. 26397020 10.1016/j.conb.2015.09.002
Okamura N Harada R Furukawa K: Advances in the development of tau PET radiotracers and their clinical applications. Ageing Res Rev. 2016;30:107-13. 26802556 10.1016/j.arr.2015.12.010
Villemagne VL Fodero-Tavoletti MT Masters CL: Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-24. 25496902 10.1016/S1474-4422(14)70252-2
Wang Y Mandelkow E: Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5-21. 26631930 10.1038/nrn.2015.1
Dickson DW Kouri N Murray ME: Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45(3):384-9. 21720721 10.1007/s12031-011-9589-0 3208128
Okamura N Furumoto S Fodero-Tavoletti MT: Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137(Pt 6):1762-71. 24681664 10.1093/brain/awu064 F1000 Recommendation
Harada R Okamura N Furumoto S: [ 18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2015;42(7):1052-61. 25792456 10.1007/s00259-015-3035-4
Harada R Okamura N Furumoto S: 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med. 2016;57(2):208-14. 26541774 10.2967/jnumed.115.164848
Chien DT Bahri S Szardenings AK: Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-68. 23234879 10.3233/JAD-122059
Maruyama M Shimada H Suhara T: Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094-108. 24050400 10.1016/j.neuron.2013.07.037 3809845 F1000 Recommendation
Cho H Choi JY Hwang MS: Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87(4):375-83. 27358341 10.1212/WNL.0000000000002892
Johnson KA Schultz A Betensky RA: Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-9. 26505746 10.1002/ana.24546 4738026 F1000 Recommendation
Ossenkoppele R Schonhaut DR Schöll M: Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551-67. 26962052 10.1093/brain/aww027 5006248 F1000 Recommendation
Schöll M Lockhart SN Schonhaut DR: PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016;89(5):971-82. 26938442 10.1016/j.neuron.2016.01.028 4779187 F1000 Recommendation
Nelson PT Alafuzoff I Bigio EH: Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-81. 22487856 10.1097/NEN.0b013e31825018f7 3560290
Murray ME Lowe VJ Graff-Radford NR: Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain. 2015;138(Pt 5):1370-81. 25805643 10.1093/brain/awv050 4407190
Schwarz AJ Yu P Miller BB: Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(Pt 5):1539-50. 26936940 10.1093/brain/aww023
Warren JD Fletcher PD Golden HL: The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol. 2012;8(8):451-64. 22801974 10.1038/nrneurol.2012.135
Ossenkoppele R Schonhaut DR Baker SL: Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77(2):338-42. 25448043 10.1002/ana.24321 4382124
Bischof GN Jessen F Fliessbach K: Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. Ann Clin Transl Neurol. 2016;3(12):934-9. 28097205 10.1002/acn3.339 5224823
Xia C Makaretz SJ Caso C: Association of In Vivo [ 18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol. 2017;74(4):427-36. 28241163 10.1001/jamaneurol.2016.5755 5470368
Selkoe DJ Hardy J: The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. 27025652 10.15252/emmm.201606210 4888851
Brier MR Gordon B Friedrichsen K: Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med. 2016;8(338):338ra66. 27169802 10.1126/scitranslmed.aaf2362 5267531
Chiotis K Saint-Aubert L Savitcheva I: Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016;43(9):1686-99. 26996778 10.1007/s00259-016-3363-z 4932128
Cho H Choi JY Hwang MS: In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-58. 27323247 10.1002/ana.24711 F1000 Recommendation
Lockhart SN Schöll M Baker SL: Amyloid and tau PET demonstrate region-specific associations in normal older people. Neuroimage. 2017;150:191-9. 28232190 10.1016/j.neuroimage.2017.02.051 5391247
Pontecorvo MJ Devous MD Sr Navitsky M: Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748-63. 28077397 10.1093/brain/aww334 5382945 F1000 Recommendation
Hanseeuw BJ Betensky RA Schultz AP: Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81(4):583-96. 28253546 10.1002/ana.24910 5404378
Vemuri P Lowe VJ Knopman DS: Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst). 2017;6:21-30. 28138510 10.1016/j.dadm.2016.12.010 5257031
Saint-Aubert L Lemoine L Chiotis K: Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12(1):19. 28219440 10.1186/s13024-017-0162-3 5319037
Marquié M Normandin MD Vanderburg CR: Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800. 26344059 10.1002/ana.24517 4900162 F1000 Recommendation
Lowe VJ Curran G Fang P: An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58. 27296779 10.1186/s40478-016-0315-6 4906968
Josephs KA Whitwell JL Tacik P: [ 18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132(6):931-3. 27645292 10.1007/s00401-016-1618-1 5107140
Kikuchi A Okamura N Hasegawa T: In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology. 2016;87(22):2309-16. 27794115 10.1212/WNL.0000000000003375 5135024
Sander K Lashley T Gami P: Characterization of tau positron emission tomography tracer [ 18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12(11):1116-24. 26892233 10.1016/j.jalz.2016.01.003
Ishiki A Harada R Okamura N: Tau imaging with [ 18 F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2017;24(1):130-6. 27797445 10.1111/ene.13164
Ng KP Pascoal TA Mathotaarachchi S: Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9(1):25. 28359327 10.1186/s13195-017-0253-y 5374697 F1000 Recommendation
Hostetler ED Walji AM Zeng Z: Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles. J Nucl Med. 2016;57(10):1599-606. 27230925 10.2967/jnumed.115.171678
Xia CF Arteaga J Chen G: [ 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9(6):666-76. 23411393 10.1016/j.jalz.2012.11.008
Barret O Alagille D Sanabria S: Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. J Nucl Med. 2017;58(7):1124-31. 27908967 10.2967/jnumed.116.182881
Jacobs AH Tavitian B INMiND consortium , Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab. 2012;32(7):1393-415. 22549622 10.1038/jcbfm.2012.53 3390799
Heneka MT Carson MJ El Khoury J: Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. 25792098 10.1016/S1474-4422(15)70016-5 F1000 Recommendation
Ransohoff RM: How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777-83. 27540165 10.1126/science.aag2590
Fowler JS Logan J Volkow ND: Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol. 2005;7(6):377-87. 16265597 10.1007/s11307-005-0016-1
Venneti S Lopresti BJ Wiley CA: The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80(6):308-22. 17156911 10.1016/j.pneurobio.2006.10.002 1849976
Liu GJ Middleton RJ Hatty CR: The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol. 2014;24(6):631-53. 25345894 10.1111/bpa.12196
Chauveau F Boutin H Van Camp N: Nuclear imaging of neuroinflammation: a comprehensive review of [ 11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304-19. 18828015 10.1007/s00259-008-0908-9
Schain M Kreisl WC: Neuroinflammation in Neurodegenerative Disorders-a Review. Curr Neurol Neurosci Rep. 2017;17(3):25. 28283959 10.1007/s11910-017-0733-2
Dupont AC Largeau B Santiago Ribeiro MJ: Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int J Mol Sci. 2017;18(4): pii: E785. 28387722 10.3390/ijms18040785 5412369
Owen DR Howell OW Tang SP: Two binding sites for [ 3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30(9):1608-18. 20424634 10.1038/jcbfm.2010.63 2949260
Owen DR Yeo AJ Gunn RN: An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1-5. 22008728 10.1038/jcbfm.2011.147 3323305
Fan Z Calsolaro V Atkinson RA: Flutriciclamide ( 18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. J Nucl Med. 2016;57(11):1753-9. 27261523 10.2967/jnumed.115.169078
Turkheimer FE Rizzo G Bloomfield PS: The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015;43(4):586-92. 26551697 10.1042/BST20150058 4613512 F1000 Recommendation
Turkheimer FE Edison P Pavese N: Reference and target region modeling of [ 11C]-( R)-PK11195 brain studies. J Nucl Med. 2007;48(1):158-67. 17204713
Yaqub M van Berckel BN Schuitemaker A: Optimization of supervised cluster analysis for extracting reference tissue input curves in ( R)-[ 11C]PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32(8):1600-8. 22588187 10.1038/jcbfm.2012.59 3421099
Presotto L Iaccarino L Bettinardi V: An automated clustering algorithm for reference region extraction of brain 11C-PK11195 studies. In: 2015 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC).San Diego, CA, USA.1-3. 10.1109/NSSMIC.2015.7582180
Stefaniak J O'Brien J: Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychiatr. 2016;87(1):21-8. 26384512 10.1136/jnnp-2015-311336
Hamelin L Lagarde J Dorothée G: Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139(Pt 4):1252-64. 26984188 10.1093/brain/aww017
Rodriguez-Vieitez E Saint-Aubert L Carter SF: Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain. 2016;139(Pt 3):922-36. 26813969 10.1093/brain/awv404 4766380 F1000 Recommendation
Kreisl WC Lyoo CH Liow JC: 11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiol Aging. 2016;44:53-61. 27318133 10.1016/j.neurobiolaging.2016.04.011 4939713
Carter SF Schöll M Almkvist O: Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53(1):37-46. 22213821 10.2967/jnumed.110.087031 F1000 Recommendation
Edison P Archer HA Gerhard A: Microglia, amyloid, and cognition in Alzheimer's disease: An [ 11C](R)PK11195-PET and [ 11C]PIB-PET study. Neurobiol Dis. 2008;32(3):412-9. 18786637 10.1016/j.nbd.2008.08.001
Wiley CA Lopresti BJ Venneti S: Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66(1):60-7. 19139300 10.1001/archneurol.2008.511 2666881
Yokokura M Mori N Yagi S: In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38(2):343-51. 20844871 10.1007/s00259-010-1612-0 F1000 Recommendation
Fan Z Okello AA Brooks DJ: Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. Brain. 2015;138(Pt 12):3685-98. 26510952 10.1093/brain/awv288
Fan Z Brooks DJ Okello A: An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain. 2017;140(3):792-803. 28122877 10.1093/brain/aww349 F1000 Recommendation
Gerhard A Pavese N Hotton G: In vivo imaging of microglial activation with [ 11C]( R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21(2):404-12. 16182554 10.1016/j.nbd.2005.08.002
Iannaccone S Cerami C Alessio M: In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord. 2013;19(1):47-52. 22841687 10.1016/j.parkreldis.2012.07.002
Fan Z Aman Y Ahmed I: Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimers Dement. 2015;11(6):608-21.e7. 25239737 10.1016/j.jalz.2014.06.016
Cagnin A Rossor M Sampson EL: In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56(6):894-7. 15562429 10.1002/ana.20332
Gerhard A Banati RB Goerres GB: [ 11C]( R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003;61(5):686-9. 12963764 10.1212/01.WNL.0000078192.95645.E6
Gerhard A Watts J Trender-Gerhard I: In vivo imaging of microglial activation with [ 11C]( R)-PK11195 PET in corticobasal degeneration. Mov Disord. 2004;19(10):1221-6. 15390000 10.1002/mds.20162
Gerhard A Trender-Gerhard I Turkheimer F: In vivo imaging of microglial activation with [ 11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 2006;21(1):89-93. 16108021 10.1002/mds.20668
Iaccarino L Moresco RM Presotto L: An In vivo 11C-(R)-PK11195 PET and In Vitro Pathology Study of Microglia Activation in Creutzfeldt-Jakob Disease. Mol Neurobiol. 2017;1-13. 28455699 10.1007/s12035-017-0522-6
Hanisch UK Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387-94. 17965659 10.1038/nn1997
Gut P Zweckstetter M Banati RB: Lost in translocation: the functions of the 18-kD translocator protein. Trends Endocrinol Metab. 2015;26(7):349-56. 26026242 10.1016/j.tem.2015.04.001
Selvaraj V Stocco DM: The changing landscape in translocator protein (TSPO) function. Trends Endocrinol Metab. 2015;26(7):341-8. 25801473 10.1016/j.tem.2015.02.007
Jucaite A Svenningsson P Rinne JO: Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015;138(Pt 9):2687-700. 26137956 10.1093/brain/awv184
Dodel R Spottke A Gerhard A: Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [ 11C] ( R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97-107. 20014118 10.1002/mds.22732
Ratchford JN Endres CJ Hammoud DA: Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259(6):1199-205. 22160466 10.1007/s00415-011-6337-x 3478150
Sucksdorff M Rissanen E Tuisku J: Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis. J Nucl Med. 2017;58(10):1646-1651. 28336784 10.2967/jnumed.116.183020
Tronel C Largeau B Santiago Ribeiro MJ: Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations. Int J Mol Sci. 2017;18(4):pii: E802. 28398245 10.3390/ijms18040802 5412386
Perry VH Nicoll JA Holmes C: Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193-201. 20234358 10.1038/nrneurol.2010.17
Price DA Martinez AA Seillier A: WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci. 2009;29(11):2177-86. 19490092 10.1111/j.1460-9568.2009.06764.x 2755595
Ahmad R Postnov A Bormans G: Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2016;43(12):2219-27. 27488857 10.1007/s00259-016-3457-7